Zydus Cadila receives tentative approval from USFDA for Droxidopa Capsules, 100 mg, 200 mg, and 300 mg

Zydus Cadila has received tentative approval from the USFDA to market Droxidopa Capsules, (US RLD: Northera®) in the strengths of 100 mg, 200 mg, and 300 mg.

Droxidopa is used to treat symptoms of low blood pressure when standing, caused by a certain medical condition (neurogenic orthostatic hypotension-nOH). This medication can lessen symptoms of low blood pressure when standing (orthostatic hypotension), such as dizziness and lightheadedness.

The drug will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.

The group now has 290 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.332.15 as compared to the previous close of Rs. 336.95. The total number of shares traded during the day was 163466 in over 3558 trades.

The stock hit an intraday high of Rs. 342.85 and intraday low of 330. The net turnover during the day was Rs. 54953072.

Source : Equity Bulls

Keywords